Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. - Wikidata - wikimedia - TriplyDB

Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial.

Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial.

http://www.wikidata.org/entity/Q43911264

about

Bisphosphonates and other bone agents for breast cancer Bisphosphonates for breast cancer Off-trial evaluation of bisphosphonates in patients with metastatic breast cancer Pharmacologic management of bone-related complications and bone metastases in postmenopausal women with hormone receptor-positive breast cancer Bisphosphonates in breast cancer Molecular Mechanisms of Bone Metastasis: Which Targets Came from the Bench to the Bedside?Bone antiresorptive agents in the treatment of bone metastases associated with solid tumours or multiple myeloma Contribution of acidic extracellular microenvironment of cancer-colonized bone to bone pain Bone-targeted therapy in metastatic breast cancer - all well-established knowledge?Randomized Controlled Trial of Zoledronic Acid plus Chemotherapy versus Chemotherapy Alone as Neoadjuvant Treatment of HER2-Negative Primary Breast Cancer (JONIE Study)Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial.Efficacy and tolerability of medical ozone gas insufflations in patients with osteonecrosis of the jaw treated with bisphosphonates-Preliminary data: Medical ozone gas insufflation in treating ONJ lesions Post-operative breast cancer patients diagnosed with skeletal metastasis without bone pain had fewer skeletal-related events and deaths than those with bone pain.Use of intravenous bisphosphonates in older women with breast cancer Comparison of the efficacy and safety of denosumab versus bisphosphonates in breast cancer and bone metastases treatment: A meta-analysis of randomized controlled trials.Atypical femoral fracture after receiving antiresorptive drugs in breast cancer patients with bone metastasis.Significant survival improvement of patients with recurrent breast cancer in the periods 2001-2008 vs. 1992-2000.The evolving role of zoledronic acid in early breast cancer Zoledronic acid and skeletal complications in patients with solid tumors and bone metastases: analysis of a national medical claims database Reverse-phase protein array for prediction of patients at low risk of developing bone metastasis from breast cancer.The role of zoledronic acid in the adjuvant treatment of breast cancer: current perspectives.Emerging therapies in metastatic bone pain.Predicting skeletal complications in metastatic breast cancer raises challenges.Hypocalcemia: updates in diagnosis and management for primary care.Zoledronate for metastatic bone disease and pain: a meta-analysis of randomized clinical trials.Improving management of patients with advanced cancer NCCN Task Force Report: Bone Health in Cancer Care.Breast cancer at bone metastatic sites: recent discoveries and treatment targets.Bisphosphonates in Breast Cancer Patients with Bone Metastases Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trial Systematic literature review and network meta-analysis comparing bone-targeted agents for the prevention of skeletal-related events in cancer patients with bone metastasis Metastatic bladder cancer: a review of current management Cost-effectiveness of zoledronic acid in the prevention of skeletal-related events in patients with bone metastases secondary to advanced renal cell carcinoma: application to France, Germany, and the United Kingdom.Acidic microenvironment and bone pain in cancer-colonized bone Optimizing clinical benefits of bisphosphonates in cancer patients with bone metastases.Treatment and Prevention of Bone Metastases from Breast Cancer: A Comprehensive Review of Evidence for Clinical Practice A randomized controlled trial to compare the efficacy of bisphosphonates in the management of painful bone metastasis Bone Health in Patients with Breast Cancer: Recommendations from an Evidence-Based Canadian Guideline Bone-Targeted Agents for the Management of Breast Cancer Patients with Bone Metastases Prevention and Treatment of Bone Metastases in Breast Cancer

P2860

Q24203656-ED7D9A08-15F8-4718-9EFB-A4DF21E0B2B8 Q24246519-B13BDFF3-B93B-4ACF-8E99-5C81D69525A6 Q24811840-3E68895B-2BBD-4380-805E-D513F32C16BD Q26746212-F5D1EDF7-6C4C-4481-8693-32D46AF101A4 Q26859326-739D8D7A-7B8F-4B65-B3A4-940D3E541D4B Q28068956-9B4AD4F3-75F7-4334-8568-609C9710EEFD Q28081996-79945F83-7985-4EB1-85B3-3B3AB2D5D9F7 Q28085753-4BA140F7-DFE0-4AF5-B68B-E50AD0CDCA5D Q28087676-207BC126-3569-42FC-A746-434509337D56 Q28551320-423853F9-98E3-4D5F-9FA3-143363BEF64F Q30416847-B8BDCF8F-7EE7-423B-A51C-AD60D2FB740D Q31048683-F8BFD8BF-89FD-4B5C-B414-C680A54287EB Q33655631-B21853C3-4ECA-4CFB-BA4D-2FF63E274D56 Q33666930-05EE6F09-E849-498D-B78C-6506EDD01B7F Q33727640-60403F72-6E7C-4D33-88CB-598823ABDB39 Q33844438-11040E65-EE62-4A96-8B87-69BC4AEF89D8 Q33858930-17276ECF-8671-4269-A360-3510DD465232 Q33915978-D454B4D4-7FD7-4790-A89C-1426C75854C0 Q33978299-B3ECB7D0-4D49-49D8-8935-4197116E934F Q34127953-3D90FA56-DECF-403D-B9E5-27CA05D070DD Q34145863-9730CB49-96D9-4352-8465-2374468E584C Q34182919-54E0A849-F90B-44A2-B6AC-2B45A6CC790E Q34247639-B4128D90-4A94-4F08-997A-1F46862476BB Q34262950-560BD9C3-9B02-46B7-9577-3CC7CD327220 Q34320376-CD96121E-2253-4CFE-8504-9127D1AD26B8 Q34413634-33590E69-56C7-4F27-9A2C-73B1CA5AC957 Q34617936-8E7E0AA6-48A7-46D7-AFEA-0968EED9AA83 Q34939979-732BF69D-0F88-4C7A-AC2B-A1F53C7C75BB Q35095548-260890AE-7D1D-42EF-B176-B4A539B3E6CB Q35141814-E77A08D7-77A0-4EE5-8D8F-58427B4CC846 Q35345620-F75340D6-1629-4C62-B42C-4E0B2AD20EB6 Q35394211-D531D7EE-26D1-4D2F-B2AC-50C1AA21D039 Q35402897-C1CBF1C9-6E6C-4878-A3FD-C64D71C606E9 Q35575632-8AF3FA56-7952-486E-88B2-B20324DD681D Q35583788-419083AE-1DBC-4DB0-8D25-7A1011179523 Q35667196-4E5A92E3-7C51-4CCD-9BFF-D7AC875D7DE7 Q35748849-2859B6E5-72C9-44F4-968C-36D7D64A30CF Q35750472-5CD58672-03B2-4030-9923-31DF4D4E2408 Q35750641-AB9C51BC-1EF2-4FB8-BABA-F30E13B1BA88 Q35750652-492BB490-EAD2-4C15-92B3-38EF38D2193B

P2860

Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial.

http://www.wikidata.org/entity/Q43911264

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年学术文章

@wuu

2005年学术文章

@zh

2005年学术文章

@zh-cn

2005年学术文章

@zh-hans

2005年学术文章

@zh-my

2005年学术文章

@zh-sg

2005年學術文章

@yue

2005年學術文章

@zh-hant

name

Zoledronic acid significantly ...... zed, placebo-controlled trial.

@en

Zoledronic acid significantly ...... zed, placebo-controlled trial.

@nl

type

label

Zoledronic acid significantly ...... zed, placebo-controlled trial.

@en

Zoledronic acid significantly ...... zed, placebo-controlled trial.

@nl

prefLabel

Zoledronic acid significantly ...... zed, placebo-controlled trial.

@en

Zoledronic acid significantly ...... zed, placebo-controlled trial.

@nl

P1433

Q43911264-287F2772-D2A4-46EC-8C8B-8803322510B3

P1476

Q43911264-C9D1D3F9-2C48-4E35-B545-BC63D5D26873

P2093

Q43911264-02670E67-63A0-44C3-8487-4E1546AFE691

Q43911264-0E4024DD-B1F9-410D-B545-1EEB559765CF

Q43911264-0F9F912C-0180-485F-BDF6-355DC0D634E7

Q43911264-3242A167-7F24-47A0-A684-D6F5A99A6DE5

Q43911264-5310D81D-0400-4B6D-992D-982D146F2E92

Q43911264-5B293893-D6AD-4E31-8FC8-AA2105C50C25

Q43911264-8E27A97E-FBE2-46F8-832A-E267501A1A53

Q43911264-A623F5A8-9E68-401B-B733-55BE813A3BFF

Q43911264-AD6A5A38-A25F-4210-B73E-7C2BC125D67C

Q43911264-E4A434E3-28DE-45E7-9ED2-3FC5DB702ED6

P304

Q43911264-24995E6B-19EB-455D-84F4-301F969CD9CF

P31

Q43911264-AB6737EC-BED4-4D0B-84A3-34D528FD7F2B

P356

Q43911264-86851A40-1145-4F81-A7B5-8A84C98F6A48

P407

Q43911264-A469F27A-C8A2-4BAF-8E7A-255F094A2676

P433

Q43911264-40023EE5-FA04-4DC7-900A-2AB4DA1B7E4F

P478

Q43911264-A6AE0A9A-D6BE-4155-A68B-A78E8A4A10F4

P577

Q43911264-4E268FB7-1753-4989-817B-60739FFE43E9

P698

Q43911264-94D4D34A-F300-46C3-ABB7-50F67D9841D7

P921

Q43911264-FA4058F9-8486-4362-8FFD-74201C6C3F2E

P356

JCO.2005.05.116

P1433

Journal of Clinical Oncology

P1476

Zoledronic acid significantly ...... zed, placebo-controlled trial.

@en

P2093

Carsten Goessl

http://www.w3.org/2001/XMLSchema#string

Hironobu Minami

http://www.w3.org/2001/XMLSchema#string

Kenjiro Aogi

http://www.w3.org/2001/XMLSchema#string

Norio Kohno

http://www.w3.org/2001/XMLSchema#string

Seigo Nakamura

http://www.w3.org/2001/XMLSchema#string

Shigemitsu Takashima

http://www.w3.org/2001/XMLSchema#string

Taro Asaga

http://www.w3.org/2001/XMLSchema#string

Toru Watanabe

http://www.w3.org/2001/XMLSchema#string

Yasuo Ohashi

http://www.w3.org/2001/XMLSchema#string

Yuichi Iino

http://www.w3.org/2001/XMLSchema#string

P304

3314-3321

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2005.05.116

http://www.w3.org/2001/XMLSchema#string

P407

P433

15

http://www.w3.org/2001/XMLSchema#string

P478

23

http://www.w3.org/2001/XMLSchema#string

P577

2005-02-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15738536

http://www.w3.org/2001/XMLSchema#string

P921